Primary metastatic carcinoma of the prostate in younger men: a plea to think over usual therapeutic strategies.
METHODS
The time from first diagnosis of primary multiple metastatic prostate carcinoma until progression and until death in patients less than 60 years old under two different therapeutic regimens was evaluated.


RESULTS
In the group with pure androgen deprivation (n = 21), the mean time until progression was 11.3 (6-55) months, the mean survival time being 21.4 (11-75) months. In the group with androgen deprivation plus cytostatic therapy (n = 10), progression was noted after 26.7 (15-77) months with a medium survival time of 26.2 (16-82) months.


CONCLUSIONS
The data argue in favor of changing the usual treatment strategy to combination therapy in "young' patients with primary metastatic prostatic cancer.
Maier
U
U
Department of Urology, University of Vienna Medical School, Austria.
Höbarth
K
K
Simak
R
R
D000328:Adult; D000728:Androgens / Q000097:blood; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D002369:Castration; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004961:Estramustine / Q000008:administration & dosage / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use; D017408:Guidelines as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D014944:World Health Organization
D000728:Androgens; D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D004961:Estramustine; D004317:Doxorubicin; D002945:Cisplatin